Ruxolitinib, izwi kandi ku izina rya ruxolitinib mu Bushinwa, ni umwe mu "miti mishya" yashyizwe ku rutonde rw’amabwiriza agenga amavuriro yo kuvura indwara z’amaraso mu myaka yashize, kandi ikaba yerekanye ingaruka nziza mu ndwara ziterwa na myeloproliferative.
Ibiyobyabwenge byibasiwe na Jakavi ruxolitinib birashobora guhagarika neza imikorere yumuyoboro wose wa JAK-STAT no kugabanya ibimenyetso byongerewe bidasanzwe byumuyoboro, bityo bikagera kubikorwa. Irashobora kandi gukoreshwa mukuvura indwara zitandukanye, no kurubuga rwa JAK1 bidasanzwe.
Ruxolitinibni inzitizi ya kinase yerekanwe kuvura abarwayi bafite myelofibrosis yo hagati cyangwa ibyago byinshi, harimo myelofibrosis yibanze, post-geniculocytose myelofibrosis, na trombocythemia myelofibrosis.
Ubushakashatsi busa n’ubuvuzi (n = 219) bwatoranije abarwayi bafite ibyago byo hagati-2 cyangwa ibyago byibanze MF, abarwayi bafite MF nyuma ya erythroblastose nyayo, cyangwa abarwayi bafite MF nyuma ya trombocytose yibanze mumatsinda abiri, umwe yakira ruxolitinib yo mu kanwa 15 kugeza kuri 20 mgbid. (n = 146) undi yakira imiti igenzura neza (n = 73). Icyiciro cyambere ningenzi byingenzi byanyuma byubushakashatsi ni ijanisha ryabarwayi bafite igabanuka rya ≥35% mubunini bwimpyiko (bisuzumwa na magnetic resonance imaging cyangwa computing tomografiya) mubyumweru 48 na 24. Ibisubizo byagaragaje ko ijanisha ry’abarwayi bafite igabanuka rirenga 35% ry’ubunini bw’intanga kuva ku cyiciro cya 24 cyari 31.9% mu itsinda ry’ubuvuzi ugereranije na 0% mu itsinda rishinzwe kugenzura (P <0.0001); n'ijanisha ry'abarwayi bafite igabanuka rirenga 35% ry'ubunini bw'intanga kuva kuri baseline ku cyumweru cya 48 byari 28.5% mu itsinda rivura ugereranije na 0% mu itsinda rishinzwe kugenzura (P <0.0001). Byongeye kandi, ruxolitinib yanagabanije ibimenyetso muri rusange kandi yazamuye ubuzima bwiza kubarwayi. Ukurikije ibisubizo by'ibi bigeragezo byombi bivura,ruxolitinibibaye imiti ya mbere yemejwe na FDA yo muri Amerika kuvura abarwayi bafite MF.